Accessibility Menu
Okyo Pharma logo

Okyo Pharma

(NASDAQ) OKYO

Current Price$1.58
Market Cap$79.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-86%
5 YearN/A
1 Year-45%
1 Month+2%

Okyo Pharma Financials at a Glance

Market Cap

$79.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.30M

EPS (TTM)

-$0.13

P/E Ratio

-12.36

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$1.58

Volume

201,273.501

Open

$1.67

Previous Close

$1.55

Daily Range

$1.55 - $1.67

52-Week Range

$1.42 - $3.35

Estimated Earnings Date

Aug 10, 2026

OKYO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Okyo Pharma

Industry

Biotechnology

CEO

Gary S. Jacob, PhD

Headquarters

London, GL W1K 1NA, GB

OKYO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

102.92%

Return on Capital

N/A

Return on Assets

-99.34%

Earnings Yield

-8.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$79.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.37M

Volume

201.27K

Avg. Volume

75.94K

Financials (TTM)

Gross Profit

-$6.82K

Operating Income

-$9.99M

EBITDA

-$9.59M

Operating Cash Flow

-$6.04M

Capital Expenditure

-$1.21K

Free Cash Flow

-$6.04M

Cash & ST Invst.

$4.22M

Total Debt

$185.80K

Okyo Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$885.00

+78.6%

Gross Margin

0.00%

N/A

Market Cap

$79.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$19.91M

N/A

Employees

4

N/A

Net Income

-$2.59M

-29238.2%

EBITDA

-$2.50M

-28544.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.22M

+4.3%

Total Debt

$185.80K

N/A

Accounts Receivable

$23.41K

-95.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$185.80K

N/A

Return on Assets

-99.34%

N/A

Return on Invested Capital

2.04%

N/A

Free Cash Flow

-$1.53M

+77.5%

Operating Cash Flow

-$1.53M

+77.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TLSATiziana Life Sciences Ltd
$1.33+8.13%
COYACoya Therapeutics, Inc.
$4.86-7.70%
PLRXPliant Therapeutics, Inc.
$1.14+1.79%
CLNNClene Inc.
$6.39+1.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$103.50-0.06%
NVDANvidia
$204.14-0.03%
IBITiShares Bitcoin Trust
$35.23-0.03%
SOFISoFi Technologies
$18.13-0.03%

Questions About OKYO

What is the current price of Okyo Pharma?

Okyo Pharma is trading at $1.55 per share.

What is the 52-week range for Okyo Pharma?

Over the past 52 weeks, Okyo Pharma has traded between $1.42 and $3.35.

How much debt does Okyo Pharma have?

As of the most recent reporting period, Okyo Pharma reported total debt of $0.00.

How much cash does Okyo Pharma have on hand?

Okyo Pharma reported $1.56M in cash and cash equivalents in its most recent financial results.

What is Okyo Pharma’s dividend yield?

Okyo Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.